Real‐world experience of budesonide orodispersible tablets in pediatric eosinophilic esophagitis

We retrospectively evaluated the effectiveness of budesonide orodispersible tablets (BOT) in children with eosinophilic esophagitis (EoE) followed up at our center. A total of 17 children were treated with BOT 0.5 mg twice daily after a median time from diagnosis of 16 months (interquartile range [IQR]: 11-28.5). Previous treatments included proton-pump inhibitors, food elimination diets, and topical swallowed corticosteroids (TSC). After 3 months, 11/17 (65%) patients were in clinical remission. 8/17 (47%) patients repeated an endoscopy after a median time of 11.5 months (6.75-16.75 IQR); 6/8 (75%) were in endoscopic remission and 7/8 (87.5%) achieved histological remission. Eosinophils count at histology significantly decreased from baseline (30 [15-50 IQR] to 6 [6-9 IQR], p = 0.03]. 3/4 (75%) patients who previously failed TSC achieved complete remission on BOT. After a median follow-up of 12.5 months (6.25-21 IQR), 11/17 (65%) patients were still on BOT treatment, and 9/11 (82%) were in clinical remission. No adverse events were reported.